Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

E Hitre; B Budai; Z Takácsi-Nagy; G Rubovszky; E Tóth; é Remenár; C Polgár; I Láng

首页> 外文期刊>British Journal of Cancer >Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

【24h】

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

机译：具有表皮生长因子受体的腺样囊性癌患者西妥昔单抗和铂类化疗或化疗：II期试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with concomitant platinum-based chemoradio- or chemotherapy in patients with locally advanced or metastatic ACC, respectively, was evaluated.

机译：背景：表皮生长因子受体（EGFR）在腺样囊性癌（ACC）中高表达。评估了西妥昔单抗与伴有铂基放化疗的化疗药物在局部晚期或转移性ACC患者中的疗效和毒性。

著录项

来源
《British Journal of Cancer》 |2013年第5期|共6页
作者
E Hitre; B Budai; Z Takácsi-Nagy; G Rubovszky; E Tóth; é Remenár; C Polgár; I Láng;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. [J] . Agulnik M, Cohen EW, Cohen RB, Journal of Clinical Oncology . 2007,第25期

机译：拉帕替尼在唾液腺表达腺样囊性癌和非腺样囊性癌的复发性或转移性表皮生长因子受体和/或erbB2的II期研究中。
2. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head [J] . Baselga J, Trigo JM, Bourhis J, Journal of Clinical Oncology . 2005,第24期

机译：抗表皮生长因子受体单克隆抗体西妥昔单抗联合铂类化学疗法在铂难治性转移性和/或复发性头颅癌患者中的II期多中心研究
3. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015) [J] . Despierre Evelyn, Vergote Ignace, Anderson Ryan, Targeted oncology . 2016,第3期

机译：表皮生长因子受体（EGFR）途径生物标志物在厄洛替尼的III期随机试验中与在无一线铂类化学疗法后无疾病进展迹象的卵巢癌患者中观察到的比较（第10卷，第583页，2015年）
4. HER1 THERAPEUTIC CANCER VACCINE: AN ACTIVE IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH TUMORS EXPRESSING THE RECEPTOR OF EPIDERMAL GROWTH FACTOR (EGF-R) [C] . Eduardo Suarez, Belinda Sanchez, Zaima Mazorra, Conference on vaccine technology VI . 2018

机译：HER1癌症治疗疫苗：一种针对表皮生长因子（EGF-R）受体的肿瘤的主动免疫疗法
5. A novel small molecule-based multi-targeting approach for the selective therapy of epidermal growth factor receptor (EGFR)- or Her2-expressing carcinomas. [D] . Banerjee, Ranjita. 2006

机译：一种新颖的基于小分子的多靶点方法，用于选择性治疗表皮生长因子受体（EGFR）或Her2表达的癌症。
6. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial [O] . E Hitre, B Budai, Z Takácsi-Nagy, 2013

机译：具有表皮生长因子受体的腺样囊性癌患者西妥昔单抗和铂类化疗或化疗：II期试验
7. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial [O] . E Hitre, B Budai, Z Takácsi-Nagy, 2013

机译：西妥昔单抗和基于铂的表皮生长因子受体患者的化学疗法表达表达腺样囊性癌：II期试验

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

摘要

著录项

相似文献

相关主题

期刊订阅